2019
Treatment of locally advanced or metastatic urothelial carcinoma: Analysis of expert and community healthcare provider practice trends.
Rosenthal K, Galsky M, Milowsky M, Petrylak D, Rosenberg J, Obholz K, Plimack E. Treatment of locally advanced or metastatic urothelial carcinoma: Analysis of expert and community healthcare provider practice trends. Journal Of Clinical Oncology 2019, 37: 389-389. DOI: 10.1200/jco.2019.37.7_suppl.389.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsCisplatin-based chemotherapyMetastatic urothelial carcinomaUrothelial carcinomaHealthcare providersExact testDifferent immune checkpoint inhibitorsPD-L1 testingFischer's exact testFDA label changePearson chi-squaredEligible ptsCheckpoint inhibitorsEligible casesTreatment indicationsTreatment decisionsClinical practicePractice trendsNew indicationsExpert recommendationsChi-squaredCarcinomaLabel changes
1999
Chemotherapy for advanced hormone refractory prostate cancer
Petrylak D. Chemotherapy for advanced hormone refractory prostate cancer. Urology 1999, 54: 30-35. PMID: 10606282, DOI: 10.1016/s0090-4295(99)00452-5.Peer-Reviewed Original ResearchConceptsHormone-refractory prostate cancerRefractory prostate cancerProstate-specific antigenProstate cancerBone painAdvanced hormone-refractory prostate cancerHormone-resistant prostate cancerSerum prostate-specific antigenCombination of estramustinePhase III studySoft tissue metastasesTaxane-based therapyCombination of mitoxantroneMetastatic prostate cancerDrug Administration approvalCorticosteroid therapyHormone therapyIII studyTissue metastasesRandomized trialsTreatment optionsHistorical controlsAdministration approvalClinical practiceUS Food